Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Myeloid 1Gynecologic 1

Conditions

Neoplasm, Residual 1

Interventions

Radiotherapy 9Drug Therapy 9Cisplatin 9Gemcitabine 8Docetaxel 7Carboplatin 7Blood Specimen Collection 7Nivolumab 6Fluorouracil 6Pemetrexed 5Capecitabine 5pembrolizumab 4Surveys and Questionnaires 4Positron Emission Tomography Computed Tomography 4Paclitaxel 4Oxaliplatin 4Exercise 4Everolimus 4Data Collection 4Cetuximab 4indibulin 3icotinib 3Vincristine 3Trastuzumab 3Standard of Care 3Radiosurgery 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Tyrosine Kinase Inhibitors × Tumor-Agnostic × Clear all
NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
82 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡